India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...

As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the sha...

The Indian stock market rallied around 3% over the last week, recouping its early losses despite global volatility. Analysts expect the mar...

This week, 573 companies will announce their June quarter results, featuring prominent firms. Bharti Airtel and Nykaa are among those repor...

Nearly 100 stocks, including Maruti Suzuki, ICICI Bank, Coforge and Vedanta Aluminium, will trade ex-date between August 3 and August 7 for...

In an exchange filing, GSM Foils said the firing incident took place in the Naikpada area in Vasai-Virar, located near Mumbai. After gettin...

Indian markets traded in a narrow range, settling marginally higher with mixed cues. Maruti Suzuki, ITC, and Vedanta shares are in focus du...

Several Indian family businesses received awards for their significant contributions. Serum Institute of India was honored for philanthropi...

India’s 3,040 richest individuals hold Rs 104 lakh crore in wealth, nearly 30% of nominal GDP, highlighting growing wealth concentration. T...

Artificial intelligence is revolutionizing the pharmaceutical sector by significantly reducing the instances of drug recalls. By improving ...

Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...

Over 110 companies, including Wipro, UltraTech Cement and Britannia, will turn ex-date this week for dividends and bonus issues. Investors ...

India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...